Study of INBRX-109 in Conventional Chondrosarcoma (ChonDRAgon)

• Drug: INBRX-109
• Drug: Placebo

Inclusion Criteria:

1. Conventional chondrosarcoma, unresectable (=inoperable) or metastatic.
2. Measurable disease by RECISTv1.1. Note: Tumor lesions located in a previously irradiated (or other locally treated) area will be considered measurable, provided there has been clear imaging-based progression of the lesions since the time of treatment.
3. Radiologic progression of disease per RECISTv1.1 criteria within 6 months prior to screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening for this study.
4. Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
5. Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group performance status (ECOG PS) of 0 or 1.
6. Estimated life expectancy of at least 12 weeks.
7. Availability of archival tissuea group of cells that work together to perform a function or fresh cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs biopsyremoval of a section of tissue to analyse for cancer cells are mandatory.